229 related articles for article (PubMed ID: 25749267)
1. Ledipasvir/sofosbuvir; ombitasvir/paritaprevir/ritonavir/dasabuvir sodium monohydrate; and peramivir.
Hussar DA; Kavelak HL
J Am Pharm Assoc (2003); 2015; 55(2):216, 219-20, 222. PubMed ID: 25749267
[No Abstract] [Full Text] [Related]
2. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
Iacob S; Cerban R; Pietrareanu C; Ester C; Iacob R; Gheorghe C; Popescu I; Gheorghe L
J Gastrointestin Liver Dis; 2018 Jun; 27(2):139-144. PubMed ID: 29922758
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study.
Janczewska E; Zarębska-Michaluk D; Berak H; Piekarska A; Gietka A; Dybowska D; Mazur W; Belica-Wdowik T; Dobracki W; Tudrujek-Zdunek M; Deroń Z; Buczyńska I; Sitko M; Czauż-Andrzejuk A; Lorenc B; Białkowska-Warzecha J; Citko J; Laurans Ł; Jaroszewicz J; Socha Ł; Tronina O; Adamek B; Horban A; Halota W; Baka-Ćwierz B; Tomasiewicz K; Simon K; Garlicki A; Wawrzynowicz-Syczewska M; Flisiak R
BMC Infect Dis; 2018 Nov; 18(1):580. PubMed ID: 30445916
[TBL] [Abstract][Full Text] [Related]
4. Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.
Steiner S; Bucsics T; Schwabl P; Mandorfer M; Scheiner B; Aichelburg MC; Grabmeier-Pfistershammer K; Ferenci P; Trauner M; Peck-Radosavljevic M; Reiberger T
Wien Klin Wochenschr; 2017 Aug; 129(15-16):517-526. PubMed ID: 28130599
[TBL] [Abstract][Full Text] [Related]
5. Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
King JR; Dutta S; Cohen D; Podsadecki TJ; Ding B; Awni WM; Menon RM
Antimicrob Agents Chemother; 2016 Feb; 60(2):855-61. PubMed ID: 26596948
[TBL] [Abstract][Full Text] [Related]
6. [Hepatitis C genotype 1. Harvoni and Holkira Pak reimbursed?].
Sabourin G
Perspect Infirm; 2015; 12(5):60. PubMed ID: 26730433
[No Abstract] [Full Text] [Related]
7. Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Isakov V; Paduta D; Viani RM; Enejosa JV; Pasechnikov V; Znoyko O; Ogurtsov P; Bogomolov PO; Maevskaya MV; Chen X; Shulman NS
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1073-1076. PubMed ID: 29762255
[TBL] [Abstract][Full Text] [Related]
8. Viral hepatitis: new hepatitis C therapies-a medical pick and mix.
Ray K
Nat Rev Gastroenterol Hepatol; 2014 Jun; 11(6):329. PubMed ID: 24776807
[No Abstract] [Full Text] [Related]
9. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection.
Smith MA; Lim A
Drug Des Devel Ther; 2015; 9():6083-94. PubMed ID: 26622169
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study.
Butt AA; Ren Y; Puenpatom A; Arduino JM; Kumar R; Abou-Samra AB
Aliment Pharmacol Ther; 2018 Jul; 48(1):35-43. PubMed ID: 29797514
[TBL] [Abstract][Full Text] [Related]
11. Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients.
Özer Etik D; Suna N; Öcal S; Selçuk H; Dağlı Ü; Çolak T; Hilmioğlu F; Boyacıoğlu AS; Haberal M
Exp Clin Transplant; 2019 Feb; 17(1):52-58. PubMed ID: 30719954
[TBL] [Abstract][Full Text] [Related]
12. Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
Khatri A; Mensing S; Podsadecki T; Awni W; Menon R; Dutta S
Clin Drug Investig; 2016 Aug; 36(8):625-35. PubMed ID: 27153823
[TBL] [Abstract][Full Text] [Related]
13. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
Kan H; Imamura M; Kawakami Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Kobayashi T; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Aikata H; Hayes CN; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
J Med Virol; 2017 Nov; 89(11):1963-1972. PubMed ID: 28657143
[TBL] [Abstract][Full Text] [Related]
14. Severe hepatotoxicity of ritonavir, ombitasvir, paritaprevir, and dasabuvir in a kidney transplant recipient.
Bukal N; Furic-Cunko V; Juric I; Katalinic L; Dedo A; Basic-Jukic N
Saudi J Kidney Dis Transpl; 2019; 30(5):1184-1186. PubMed ID: 31696862
[No Abstract] [Full Text] [Related]
15. Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir.
Todt D; Schlevogt B; Deterding K; Grundhoff A; Manns MP; Wedemeyer H; Fischer N; Cornberg M; Steinmann E
J Antimicrob Chemother; 2017 May; 72(5):1541-1543. PubMed ID: 28100444
[No Abstract] [Full Text] [Related]
16. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Klibanov OM; Gale SE; Santevecchi B
Ann Pharmacother; 2015 May; 49(5):566-81. PubMed ID: 25680759
[TBL] [Abstract][Full Text] [Related]
17. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Feld JJ; Kowdley KV; Coakley E; Sigal S; Nelson DR; Crawford D; Weiland O; Aguilar H; Xiong J; Pilot-Matias T; DaSilva-Tillmann B; Larsen L; Podsadecki T; Bernstein B
N Engl J Med; 2014 Apr; 370(17):1594-603. PubMed ID: 24720703
[TBL] [Abstract][Full Text] [Related]
18. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Andreone P; Colombo MG; Enejosa JV; Koksal I; Ferenci P; Maieron A; Müllhaupt B; Horsmans Y; Weiland O; Reesink HW; Rodrigues L; Hu YB; Podsadecki T; Bernstein B
Gastroenterology; 2014 Aug; 147(2):359-365.e1. PubMed ID: 24818763
[TBL] [Abstract][Full Text] [Related]
19. [All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection].
Höner zu Siederdissen C; Cornberg M
Dtsch Med Wochenschr; 2014 Nov; 139(47):2411-4. PubMed ID: 25390631
[No Abstract] [Full Text] [Related]
20. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Petta S; Marzioni M; Russo P; Aghemo A; Alberti A; Ascione A; Antinori A; Bruno R; Bruno S; Chirianni A; Gaeta GB; Giannini EG; Merli M; Messina V; Montilla S; Perno CF; Puoti M; Raimondo G; Rendina M; Silberstein FC; Villa E; Zignego AL; Pani L; Craxì A; ;
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):427-434. PubMed ID: 28497758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]